Exploring Zanidatamab (ZW25): A Bispecific Antibody with Potential to be the Next Foundational Treatment for HER2-Experssing Cancers

Time: 3:30 pm
day: Day One


• Zanidatamab is a humanized, bispecific, IgG1-like antibody directed against the juxtamembrane domain (ECD4) and the dimerization domain (ECD2) of HER2
• Zanidatamab’s unique binding properties result in: receptor clustering, internalization, and downregulation; inhibition of growth factor-dependent and independent tumor cell proliferation; antibody-dependent cellular cytotoxicity and phagocytosis, and complement-dependent cytotoxicity
• Zanidatamab has demonstrated durable anti-tumor activity in patients as a single agent and in combinations across different HER2 expressing tumor types including biliary tract cancer, gastroesophageal adenocarcinoma (GEA), and breast cancer
• The global development for zanidatamab will be discussed including first-line treatment in GEA in combination with chemotherapy